A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

89 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-30

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 12weeks and a follow up phase for 4weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low-dose IL-2 Treatment on Behcet's Disease

NCT04065672

Behcet's Disease

COMPLETED PHASE2

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

NCT00866359

Behcet Syndrome

COMPLETED PHASE2

Tocilizumab for the Treatment of Refractory Behcet's Uveitis

NCT03554161

Behcet Syndrome Uveitis

TERMINATED PHASE2

A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis

NCT04021862

Atopic Dermatitis Eczema

COMPLETED PHASE2

Golimumab for the Treatment of Refractory Behcet's Uveitis

NCT04218565

Behcet Syndrome Uveitis

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

this study is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study to evaluate Hemay005 efficacy and safety of the treatment of patients with Behçet Disease(BD). Around 252 subjects will be randomized into this study.

The whole study will including 4 phases that a screening phase, core-treatment phase(12weeks), extended-treatment phase (12weeks) and follow-up phase(4 weeks).

Screening: All subjects will undergo a screening period of up to 6 weeks prior to baseline visit (visit 2, day of randomization, Day0).

Core treatment phase: eligible BD patients will randomly assigned to Hemay005 high-dose group, Hemay005 low-dose group, placebo (core treatment phase) + Hemay005 high-dose group (extended treatment phase), or placebo (core treatment phase) + Hemay005 low-dose group (extended treatment phase). During the core-treatment period, hemay005 will be administered twice daily for 12 weeks. The randomization was stratified to minimize the imbalance between treatment groups.

Extended treatment phase: Subjects in the high-dose and low-dose groups during the extended treatment period will still given the dose of core-treatment phase for 12 weeks. Subjects who received placebo during the core treatment will assigned to either a high-dose group or a low-dose group according the allocation at visit 2 until 12 weeks after. During this period, the subject and investigator are remain blind at this stage.

Follow up phase: Subjects in the study (also including those who withdraw from treatment for any reason) will have another follow up for 4 weeks after the end of the last administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Behçet Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemay005 high dose group

In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.

Group Type EXPERIMENTAL

Hemay005

Intervention Type DRUG

Hemay005 tables 60mg bid p.o;

Hemay005 lower dose group

In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.

Group Type EXPERIMENTAL

Hemay005

Intervention Type DRUG

Hemay005 tables 45mg bid p.o

Placebo

In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.

Group Type PLACEBO_COMPARATOR

Hemay005

Intervention Type DRUG

Hemay005 tables 60mg bid p.o;

Hemay005

Intervention Type DRUG

Hemay005 tables 45mg bid p.o

Placebo

Intervention Type OTHER

placebo to Hemay005 tables bid p.o

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hemay005

Hemay005 tables 60mg bid p.o;

Intervention Type DRUG

Hemay005

Hemay005 tables 45mg bid p.o

Intervention Type DRUG

Placebo

placebo to Hemay005 tables bid p.o

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Phosphodiesterase 4 (PDE4) inhibitors Phosphodiesterase 4 (PDE4) inhibitors

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1.Understand and voluntarily sign an informed consent form prior to any study related assessments/procedures being conducted.
* 2.Male and female subjects 18\~75(inclusive) years of age at the time of signing the informed consent form.
* 3.Diagnosed with Behçet's disease meeting the International Study Group (ISG) criteria (2013).
* 4.Subjects must have at least 2 oral ulcers at V1, and:

1. at least 2 oral ulcers at V2 if V2 occurs at least 14 days after Visit 1, OR
2. at least 3 oral ulcers at V2 if V2 occurs at least 0\~42 days after Visit 1.
* 5\. According to the site investigator judgement, subject is suitable to the systemic but not topical treatment of oral ulcer considering the severity and affected area of the disease OR the oral ulcer cannot be well controlled by topical treatment and have to take the systemic treatment.
* 6.All females of childbearing potential (FCBP) and male subjects who did not receive the vasectomy must take effective contraceptive measures.

Exclusion Criteria

* 1.subject has the BD related major organ activity lesions requiring immunosuppressive therapy- pulmonary, vascular, gastrointestinal, and central nervous systems (eg, meningoencephalitis) manifestations, etc. However:

1. Previous major organ involvement is allowed if it occurred at least one years prior to screening visit and is not active at time of enrollment.
2. Subjects with BD-related arthritis and BD-skin manifestations are also allowed
* 2\. Any clinically significant heart disease (e.g., but not limited to unstable ischemic heart disease, New York Heart Association(NYHA) class III / IV left ventricular failure, or myocardial infarction) or clinically significant 12 lead ECG abnormalities found during screening, which, according to the investigator's judgment, may put the patient at safety risk or may interfere with the investigator;
* 3\. subjects who current receiving immunotherapy including:

1. 7 days prior to Visit 2 (randomization) for colchicine.
2. 10 days prior to Visit 2 (randomization) for azathioprine, mycophenolate mofetil, baricitinib or Tofacitinib.
3. 4 weeks prior to visit 2(randomization) for cyclosporin, methotrexate, cyclophosphamide, thalidomide, and dapsone.
4. At least 5 terminal half-lives for all biologics, including,within:

1. Four weeks prior to visit 2(randomization) for etanercept.
2. Eight weeks prior to visit 2(randomization) for infliximab.
3. Ten weeks prior to visit 2(randomization) for adalimumab, golimumab, abatacept, and tocilizumab.
4. Six months prior to visit 2(randomization) for secukinumab.
* 4.Having received intra-articular or parenteral corticosteroids within 6 weeks (42 days) prior to Visit 2.
* 5.Laboratory examination of V1 in screening period:

1. Hemoglobin ≤ 85g / L;
2. The white blood cell (WBC) count was less than 3.0 × 10\^9 / L or more than 14 × 10\^9 / L;
3. Platelet \< 100 × 10\^9 / L;
4. Serum creatinine \> 1.5mg/dl (\> 132.6 μ mol / L);
5. Total bilirubin \> 2.0 mg / dl (\> 34.2 μ mol / L);
6. The Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) were higher than 1.5 times of the upper limit of normal value.
* 6.subjects who received strong cytochrome P450 enzyme inducer within 4 weeks prior to visit2.
* 7.Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C and herpes zoster, histoplasmosis, coccidiomycosis, but excluding onychomycosis) , judged by investigator,may put the patient at safety risk.
* 8.Clinically significant abnormality on chest radiograph or CT,judged by investigator, may put the patient at safety risk.
* 9.History of transplantation and immunodeficiency disease, including those subject has a positive test for human immunodeficiency virus (HIV).
* 10.subject who use of any investigational products of clinical trials within 4 weeks or within 5 pharmacokinetic/pharmacodynamic half-lives prior to randomization, whichever is longer;
* 11.known to be allergic or allergic to the investigational products or ingredients;
* 12.History of alcohol or drug abuse, or a history of mental illness;
* 13.Subjects with severe, progressive, or uncontrolled disease, judged by the investigator, who maybe at risk if participate this study or those subjects whose participation may influence the interpretation of study results.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

zhanguo Li, Doctor

Role: PRINCIPAL_INVESTIGATOR

Peking University People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital of Bengbu Medical College

Bengbu, Anhui, China

Site Status